Drug intelligence / Profile preview

NTX2R13

Development stage: Preclinical
Lead developer: Nectin Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NTX2R13 is a monoclonal antibody being developed by Nectin Therapeutics for the treatment of solid tumors. It specifically targets CD112R (also known as PVRIG), an inhibitory immune checkpoint receptor expressed on T cells and natural killer (NK) cells. CD112R interacts with its ligand CD112 (Nectin-2), which is frequently overexpressed on various cancer cells, leading to the suppression of immune cell activity. By blocking this interaction, NTX2R13 is designed to restore and enhance the anti-tumor immune response. The program is currently in the IND-enabling stage of development.

Targets

PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)

Beyond the preview

Go deeper on NTX2R13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX2R13.

Explore the full profile